Abstract | BACKGROUND: METHODS: We determined ADAM8 levels in the serum of 79 HNSCC patients at the time of diagnosis, in 35 patients 3 months after treatment and in 10 patients 1 year after therapy and compared the results to the sera of 31 healthy volunteers. We also constructed tissue microarrays to detect ADAM8 immunohistochemically in 100 patients. The results were correlated with the survival data of the patients to determine the diagnostic and prognostic value. RESULTS: The data demonstrated that patients with high ADAM8 expression in the tumor have worse survival rates. We found that high ADAM8 serum levels correlated with high ADAM8 expression in tumor samples. Soluble ADAM8 levels did not show any prognostic or diagnostic properties. CONCLUSION:
|
Authors | Valerie Zielinski, Markus Brunner, Gregor Heiduschka, Sven Schneider, Rudolf Seemann, Boban Erovic, Dietmar Thurnher |
Journal | BMC cancer
(BMC Cancer)
Vol. 12
Pg. 76
(Feb 27 2012)
ISSN: 1471-2407 [Electronic] England |
PMID | 22369429
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Membrane Proteins
- ADAM Proteins
- ADAM8 protein, human
|
Topics |
- ADAM Proteins
(metabolism)
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(metabolism)
- Carcinoma, Squamous Cell
(diagnosis, metabolism, mortality)
- Enzyme-Linked Immunosorbent Assay
- Female
- Head and Neck Neoplasms
(diagnosis, metabolism, mortality)
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Male
- Membrane Proteins
(metabolism)
- Microarray Analysis
- Middle Aged
- Prognosis
- Retrospective Studies
|